


FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. SCIOS.002C1	APPLICATION NO. 10/083,817
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		<div style="text-align: right;">RECEIVED</div> <div style="text-align: right;">NOV 29 2002</div>	
(USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Schreiner, et al.	GROUP 1647
		FILING DATE February 26, 2002	TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS
CS	1	4,456,550 A	06/1984	Dvorak et al.		
	2	5,194,596 A	03/1993	Tischer et al.		
	3	5,219,739 A	06/1993	Tischer et al.		
	4	5,240,848 A	08/1993	Keck et al.		
	5	5,332,671 A	07/1994	Ferrara et al.		
CS	6	6,352,975 B1	03/2002	Schreiner et al.		

FOREIGN PATENT DOCUMENTS						
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS
CS	7	0 464 155 B1	05/1997	Europe		
CS	8	WO 98/20027	05/1998	W.I.P.O.		

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
CS	9	Johnson and Schreiner, <i>Kidney Int.</i> 52:1169-1179 (1998).
	10	Johnson et al., <i>Hypertension</i> 19:464-474 (1992).
	11	Roberts and Palade, <i>J. Cell Sci.</i> 108:2369-2379 (1995).
	12	Esser et al., <i>J. Cell. Biol.</i> 140:947-959 (1998).
	13	Kramer et al., <i>Kidney Int.</i> 51:444-447 (1997).
	14	Shulman et al., <i>J. Am. Soc. Nephrol.</i> 7:661-666 (1996).
	15	Ferrara and Davis-Smyth, <i>Endocrine Rev.</i> 18:4-25 (1997)
	16	Monacchi et al., <i>Am. J. Physiol.</i> 264:C995-C1002 (1993).
	17	Hariawala et al., <i>J. Surgical Res.</i> 63:77-82 (1996).
	18	Sellke et al., <i>Am. J. Physiol.</i> 271:H713-H720 (1996).
	19	Henry et al., <i>J. Am. Coll. Cardio.</i> 32(2; Suppl. A):65A (1998).
	20	Lombardi et al., <i>Hypertension</i> 33:1013-1019 (1999).
	21	Klagsburn and D'Amore, <i>Cytokine and Growth Factor Reviews</i> 7:259-270 (1996).
CS	22	Kaplan et al., <i>Pediatr. Nephrol.</i> 4:276 (1990).

EXAMINER <i>C. Saoud</i>	DATE CONSIDERED <i>9/30/03</i>
<small>*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</small>	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. SCIOS.002C1	APPLICATION NO. 10/083,817
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Schreiner, et al.	RECEIVED NOV 29 2002 TECH CENTER 1600/2900
		FILING DATE February 28, 2002	

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
CA	23 Remuzzi and Ruggenti, <i>Kidney Int.</i> , 48:2-19 (1995).
	24 Neilson and Couser eds., <i>Immunologic Renal Diseases</i> , Lippincott-Raven Philadelphia, 1996, pp. 1161-1181.
	25 Habib et al., <i>Adv. Nephrol.</i> 11:99-128 (1982).
	26 Nangaku et al., <i>Kidney Int.</i> 52:1570-1578 (1997).
	27 Nangaku et al., <i>Kidney Int.</i> 52:182-194 (1997).
	28 Nangaku et al., <i>Curr. Opin. Nephrol. Hypertens.</i> 7:457-462 (1998).
	29 Gerber et al., <i>J. Biol. Chem.</i> 273:3-336-30343 (1998).
	30 Spyridopoulos et al., <i>J. Mol. Cell Cardiol.</i> 29:1321-1330 (1997) [erratum published in <i>J. Mol. Cell Cardiol.</i> 30:897 (1998)].
	31 Gerber et al., <i>Development</i> 126:1149-1159 (1999).
	32 Takeshita et al., <i>J. Clin. Invest.</i> 93:662-670 (1994).
	33 Iruela et al., <i>Am. J. Pathol.</i> 147:1715-1727 (1995).
	34 Kitamura et al., <i>Exp. Nephrol.</i> 6:328-336 (1998).
	35 Tudor et al., <i>J. Clin. Invest.</i> 95:1798-1807 (1995).
	36 Banai et al., <i>Circulation</i> 89:2183-2189 (1994).
	37 Alon et al., <i>Nat. Med</i> 1:1024-1028 (1995).
	38 Benjamin et al., <i>J. Clin. Invest.</i> 103:159-165 (1999).
	39 Papapetropoulos et al., <i>Clin. Invest.</i> 100:3131-3139 (1997).
	40 Wu et al., <i>Am. J. Physiol.</i> 271:H2735-2739 (1996).
	41 Ku et al., <i>Am. J. Physiol.</i> 265:H586-592 (1993).
	42 Gordjani et al., <i>Semin. Thromb. Hemost.</i> 23:281-293 (1997).
	43 Concepcion et al., "Tissue availability of insulin-like growth factor I is inversely related to insulin resistance in essential hypertension: Effects of angiotensin converting enzyme inhibition." <i>Journal of Hypertension</i> . 16(6):863-870 (1998).
	44 Abstract. XP-002134130.
CA	45 Voelkel et al., (1996) "Vascular endothelial growth factor in pulmonary hypertension." <i>Annals of the New York Academy of Sciences</i> . 186-93 (1996).

S:\DOCS\JMM\JM-9255.DOC
112102

EXAMINER C. Saoud	DATE CONSIDERED 9/30/03
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	